Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement. | Hemasphere | 2023 | 38044958 | PubTator, text mining | PubMed |
| Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansion. | Sci Immunol | 2023 | 38039376 | PubTator, text mining | PubMed |
| EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. | Sci Adv | 2023 | 38039357 | PubTator, text mining | PubMed |
| Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies. | Technol Cancer Res Treat | 2023 | 38037341 | PubTator, text mining | PubMed |
| A CRISPR-Cas9 library screening identifies CARM1 as a critical inhibitor of ferroptosis in hepatocellular carcinoma cells. | Mol Ther Nucleic Acids | 2023 | 38028203 | PubTator, text mining | PubMed |
| CAR-T cell therapy for hematological malignancies: History, status and promise. | Heliyon | 2023 | 38027932 | PubTator, text mining | PubMed |
| CAR-T Cell Therapy for Classical Hodgkin Lymphoma. | Hemasphere | 2023 | 38026793 | PubTator, text mining | PubMed |
| CAR-T cells for pediatric malignancies: Past, present, future and nursing implications. | Asia Pac J Oncol Nurs | 2023 | 38023730 | PubTator, text mining | PubMed |
| Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy. | Bioeng Transl Med | 2023 | 38023726 | PubTator, text mining | PubMed |
| Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment. | Front Oncol | 2023 | 38023191 | PubTator, text mining | PubMed |
| Autologous CIK cells combined with chemotherapy as the first-line treatment for locally advanced or metastatic gastric cancer is safe and feasible. | Front Immunol | 2023 | 38022664 | PubTator, text mining | PubMed |
| The application, safety, and future of ex vivo immune cell therapies and prognosis in different malignancies. | Bioimpacts | 2023 | 38022382 | PubTator, text mining | PubMed |
| Current trends of clinical trials involving CRISPR/Cas systems. | Front Med (Lausanne) | 2023 | 38020120 | PubTator, text mining | PubMed |
| Immune checkpoint inhibitors for multiple myeloma immunotherapy. | Exp Hematol Oncol | 2023 | 38017516 | PubTator, text mining | PubMed |
| The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors. | Biomark Res | 2023 | 38017494 | PubTator, text mining | PubMed |
| Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells. | Cancer Cell Int | 2023 | 38012684 | PubTator, text mining | PubMed |
| Ex-vivo CS1-OKT3 dual specific bivalent antibody-armed effector T cells mediate cellular immunity against multiple myeloma. | Sci Rep | 2023 | 38012196 | PubTator, text mining | PubMed |
| Progress in oncolytic viruses modified with nanomaterials for intravenous application. | Cancer Biol Med | 2023 | 38009779 | PubTator, text mining | PubMed |
| Therapeutic avenues for γδ T cells in cancer. | J Immunother Cancer | 2023 | 38007241 | PubTator, text mining | PubMed |
| Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. | J Immunother Cancer | 2023 | 38007239 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=15